Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma.
Garfield
David H
DH
Cadranel
Jacques L
JL
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000145:classification* / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008954:Models, Biological; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D016159:Tumor Suppressor Protein p53; D000069286:Bortezomib